Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Idenix Pharma Says IDX184 Placed On Partial Clinical Hold By FDA - Quick Facts

8/16/2012 8:08 AM ET

Idenix Pharmaceuticals Inc. (IDIX: Quote) announced that it received verbal notice from the U.S. Food and Drug Administration or FDA that a partial clinical hold has been placed on IDX184, the Company's nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV).

As a result of the recent occurrence of a serious cardiac-related adverse event encountered with a competitor's nucleotide polymerase inhibitor for the treatment of HCV, the FDA has expressed an interest in further reviewing the safety of IDX184 and has placed IDX184 on partial clinical hold.

In previous clinical trials as well as the ongoing phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV), there has been no evidence to date of cardiotoxicity in patients dosed with IDX184 with PegIFN/RBV beyond that seen with PegIFN/RBV alone. There are currently no patients receiving IDX184 worldwide.

The company noted that the FDA has requested additional data on patients treated with IDX184. Patient safety is our main concern and Idenix will immediately begin work to comply with the FDA request and expects to submit these data to the FDA in the coming weeks.

The company noted that it intends to have an ongoing discussion with the FDA following the submission of this data.

Register
To receive FREE breaking news email alerts for Idenix Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Data storage solutions provider EMC Corp. (EMC) reported that net income attributable to the company for first-quarter 2014 declined to $392 million or $0.19 per share, from $580 million or $0.26 per share in the same quarter last year. Non-GAAP net income attributable to the company was $728 million... U.K. Chancellor George Osborne achieved his budget deficit target for 2013/14 as buoyant economic growth boosted tax receipts. Data from the Office for National Statistics on Wednesday showed that net borrowing totaled GBP 107.7 billion in the fiscal year ended March 2014, the lowest since the 2008/2009 financial crisis. Thailand's central bank left its key interest rate unchanged on Wednesday, after trimming it in the previous month amid the lingering political impasse. The Monetary Policy Committee of the Bank of Thailand voted 6-1 to leave the main policy rate unchanged at 2 percent, which is the lowest level since December 2010. The decision was in line with economists' expectations.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.